bms-986004
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2014 (NCT02273960)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD40 ligandINHIBITOR
CD40LG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986004
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03605927 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Bristol-Myers Squibb, University of South Florida |
| NCT02273960 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2014 | Bristol-Myers Squibb |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 1 | 1 | 2014 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1